leisure time -WSS

leisure time

author：comprehensive 2025-09-30 00:03:51 - browse：149

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Cybersecurity threat forces Lurie Children's to take systems offline

Wikipedia

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Vertigo drug brings hope for rare neuron disorder, Niemann

Medicare says breakthrough device reimbursement rule to come by summer

What nurses really want: sufficient staffing for patient care

Commercial surrogacy can be ethical, despite pope’s claims

Dairy farmers resist CDC push for PPE against bird flu virus

Wikipedia

leisure time

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Medical leaders decry Supreme Court decision on affirmative action

Medicare says breakthrough device reimbursement rule to come by summer

Apple is now the first public company to be valued at $3 trillion

Vertex non

How one medical school became remarkably diverse

Cognito secures funding to test medical device for Alzheimer's

Trump demands the U.S. pay no more for drugs than other countries … again

The lessons of Aduhelm, an Alzheimer's drug that was not to be

explore

Woodcock on FDA’s accelerated approval and her next chapter

Telehealth startups turn to complex chronic diseases

How to improve immunocompromised access to mAb treatments

ARCH Venture Partners is raising $3 billion for a life sciences fund

Some dementia cases could be undiagnosed liver disease

Juul spent big to court Black leaders to promote its e

focus

Wikipedia

focus

explore